Abstract
The aim of the study was to evaluate the prevalence of pheochromocytoma (PHEO) in patients with neurofibromatosis type 1 (NF1), and to analyze the behavior of some anthropometric and cardiovascular parameters. In 48 consecutive NF1 patients, urinary metanephrines and vanillylmandelic acid excretion were assessed. The body mass index (BMI), waist circumference (WC), ambulatory blood pressure monitoring (ABPM), echocardiography and ultrasound carotid arterial wall evaluation were performed. In NF1 patients, 11 (29.3%) had arterial hypertension, 7 (14.6%) had a PHEO. Four (57%) NF1 patients with PHEO were symptomatic at the diagnosis. In PHEO-NF1 patients, we revealed a lower BMI and WC values with respect to NF1 patients without PHEO and normal subjects (NSs) (p < 0.05), respectively. The nocturnal non-dipping pattern at the ABPM was present in 40.4% of NF1 patients, and in particular this phenomenon was present in PHEO-NF1 patients (71.4%). Left ventricular mass index and intima media thickness were significantly higher in NF1 patients as compared to NS (p < 0.05), particularly in NF1-PHEO patients (p < 0.05). In conclusions, these findings revealed high prevalence of PHEO in NF1 patients and suggest that, in addition to blood pressure, humoral factors (increased sympathetic activity or neurofibromin), influence the pathogenesis of remodeling of cardiovascular system.
Similar content being viewed by others
References
Bausch B, Borozdin W, Mautner VF et al (2007) Germline NF1 mutational spectra and loss-of-heterozygosity analyses in patients with pheochromocytoma and neurofibromatosis type 1. J Clin Endocrinol Metab 92(7):2784–2792
Bravo EL, Tagle R (2003) Pheochromocytoma: state-of-the-art and future prospects. Endocr Rev 24:539–553
Ceruti M, Petramala L, Cotesta D et al (2006) Ambulatory blood pressure monitoring in secondary arterial hypertension due to adrenal diseases. J Clin Hypertens 8:642–648
Cichowski K, Jacks T (2001) NF1 tumor suppressor gene function: narrowing the GAP. Cell 104:593–604
Cotesta D, Erlic Z, Petramala L et al (2008) Coincidence of neurofibromatosis Type 1 and multiple endocrine neoplasia type 2. Endocrinologist 18:277–281
Denolle T, Chatellier G, Julien J et al (1993) Left ventricular mass and geometry before and after etiologic treatment in renovascular hypertension, aldosterone-producing adenoma, and pheochromocytoma. Am J Hypertens 6:907–913
Ferner RE, Huson SM, Thomas N et al (2007) Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet 44(2):81–88
Friedman JM (1999) Epidemiology of neurofibromatosis type 1. Am J Med Genet 89:1–6
Gabriel KR (1997) Neurofibromatosis. Curr Opin Pediatr 9:89–93
Goldberg NS, Roenigk RK (1996) Neurofibromatosis, tuberous sclerosis, and other neurocutaneous discorde. In: Wintronb BU (ed) Cutaneous medicine and surgery: an interpretated program in dermatology. WB Saunders, Philadelpfia, pp 1729–1741
Goldstein DS, Eisenhofer G, Flynn JA et al (2004) Diagnosis and localization of pheochromocytoma. Hypertension 43:907–910
Gutmann DH, Aylsworth A, Carey JC et al (1997) The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 278:51–57
Hansen TW, Jeppesen J, Rasmussen S, Ibsen H, Torp-Pedersen C (2006) Ambulatory blood pressure monitoring and risk of cardiovascular disease: a population based study. Am J Hypertens 19(3):243–250
Heineke J, Molkentin JD (2006) Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol 7:589–600
Heniford BT, Arca MJ, Walsh RM, Gill IS (1999) Laparoscopic adrenalectomy for cancer. Semin Surg Oncol 16(4):293–306
Huson SM, Compston DA, Clark P et al (1989) A genetic study of von Recklinghausen neurofibromatosis in south east Wales. I. Prevalence, fitness, mutation rate, and effect of parental transmission on severity. J Med Genet 26:704–711
Ito Y, Fujimoto Y, Obara T (1992) The role of epinephrine, norepinephrine, and dopamine in blood pressure disturbances in patients with pheochromocytoma. World J Surg 16:759–763
Jenne DE, Tinschert S, Reimann H et al (2001) Molecular characterization and gene content of breakpoint boundaries in patients with neurofibromatosis type 1 with 17q11.2 microdeletions. Am J Hum Genet 69:516–527
Kurpad AV, Khan K, Calder AG, Elia M (1994) Muscle and whole body metabolism after norepinephrine. Am J Physiol 266:E877–E884
La Batide-Alanore A, Chatellier G, Plouin PF (2003) Diabetes as a marker of pheochromocytoma in hypertensive patients. J Hypertension 21:1703–1707
Lakkis MM, Epstein JA (1998) Neurofibromin modulation of Ras activity is required for normal endocardial-mesenchymal transformation in the developing heart. Development 125:4359–4367
Lenders JW, Eisenhofer G, Mannelli M et al (2005) Phaeochromocytoma. Lancet 366:665–675
Mancia G, Ferrari A, Gregorini L et al (1983) Blood pressure and heart rate variabilities in normotensive and hypertensive human beings. Circ Res 53:96–104
Mannelli M, Ianni L, Cilotti A et al (1999) Pheochromocytoma in Italy: a multicentric retrospective study. Eur J Endocrinol 141:619–624
Millar-Craig MW, Bishop CN, Raftery EB (1978) Circadian variation of blood-pressure. Lancet 1:795–797
Norton KK, Xu J, Gutmann DH (1995) Expression of the neurofibromatosis I gene product, neurofibromin, in blood vessel endothelial cells and smooth muscle. Neurobiol Dis 2:13–21
O’Brien E, Sheridan J, O’Malley K (1988) Dippers and non-dippers. Lancet 2:397
Pacak K, Linehan WM, Eisenhofer G et al (2001) Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. Ann Intern Med 134:315–329
Palatini P, Penzo M, Racioppa A et al (1992) Clinical relevance of nighttime blood pressure and of daytime blood pressure variability. Arch Intern Med 152:1855–1860
Rizzoni D, Muiesan ML, Porteri E et al (1998) Relations between cardiac and vascular structure in patients with primary and secondary hypertension. J Am Coll Cardiol 32:985–992
Routledge F, McFetridge-Durdle J (2007) Non-dipping blood pressure patterns among individuals with essential hypertension: a review of the literature. Eur J Cardiovasc Nurs 6:9–26
Shub C, Cueto-Garcia L, Sheps SG et al (1986) Echocardiographic findings in pheochromocytoma. Am J Cardiol 57:971–975
Tedesco MA, Di Salvo G, Natale F, Pergola V, Calabrese E, Grassia C, Ratti G, Iarussi D, Iacono A, Calabrò R, Lama G (2002) The heart in neurofibromatosis type 1: an echocardiographic study. Heart J. 143:883–888
Walther MM, Herring J, Enquist E et al (1999) von Recklinghausen’s disease and pheochromocytomas. J Urol 162:1582–1586
Xu J, Ismat FA, Wang T et al (2009) Cardiomyocyte-specific loss of neurofibromin promotes cardiac hypertrophy and dysfunction. Circ Res 105:304–311
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zinnamosca, L., Petramala, L., Cotesta, D. et al. Neurofibromatosis type 1 (NF1) and pheochromocytoma: prevalence, clinical and cardiovascular aspects. Arch Dermatol Res 303, 317–325 (2011). https://doi.org/10.1007/s00403-010-1090-z
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00403-010-1090-z